Kintor Pharmaceutical Limited

Price Chart

Risk-Adjusted Performance

Kintor Pharmaceutical Limited (KNTPF) Price Performance

Kintor Pharmaceutical Limited (KNTPF) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $0.43, down 23.44% from the previous close.

Over the past year, KNTPF has traded between a low of $0.15 and a high of $0.57. The stock has gained 182.8% over this period. It is currently 23.4% below its 52-week high.

Kintor Pharmaceutical Limited has a market capitalization of $265.02M.

About Kintor Pharmaceutical Limited

Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People's Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is developing GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer; GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC); and ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.